High-Risk Pregnancy: Clinical Trials

The NICHD conducts and supports a variety of clinical research related to high-risk pregnancy. Select a link below to learn more about these projects.

Featured NICHD Clinical Trials

  • Pravastatin for Prevention of Preeclampsia
    The purpose of this study is to determine the pharmacokinetic parameters and collect preliminary safety data for pravastatin when used as a prophylactic daily treatment in pregnant women at high risk for preeclampsia.
  • Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
    Infants born between 34 and 36 weeks of gestation, known as "late preterm," are more likely to be admitted to a special care nursery and more likely to have respiratory complications than infants born at term. The use of antenatal corticosteroids has been shown to improve lung function in very premature infants but has not been evaluated in those likely to deliver in the late preterm period. This research study aims to answer the following primary research question: Do steroids, compared with no steroids, decrease infants’ need for oxygen support when given to pregnant women at least 12-24 hours before they deliver at 34 weeks to 36 weeks gestation? The research study will also collect information on whether steroids improve the chances that the infant will not get sick from other causes.
  • Biological Markers of Disease in the Prediction of Preterm Delivery, Preeclampsia and Intra-Uterine Growth Retardation: A Longitudinal Study
    Preterm delivery, preeclampsia, and intrauterine growth restriction are leading causes of perinatal morbidity and mortality. Efforts to treat these syndromes have not been effective, most likely because these obstetric complications are the clinical expression of adaptive mechanisms of host defense developed in response to pathologic insults. Because the ultimate pathologic basis of disease is unclear, therapy for these syndromes has been largely directed at symptoms, which appear late in the development of the disease. The main purpose of this study is to perform an early and comprehensive exploration of maternal and fetal factors that predict the subsequent development of these obstetric complications so that early medical interventions may be tested in patients at high and low risk for adverse perinatal outcome.
  • Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be (nuMoM2b)
    Very little research has been conducted on nulliparous, or first-time, pregnancies. The nuMoM2b study will collect data from a diverse population of 10,000 women who are having their first child and are carrying only one fetus. The women are enrolled early in pregnancy and undergo research assessments four times during their pregnancies. The goal of the research is to find ways to identify women in this group who will develop a problem with their pregnancy and use this information to improve the health of pregnant women and their fetuses in the future. The study focuses on such pregnancy problems as preeclampsia, preterm birth, and poor fetal growth.
  • Surgical Procedures to Prevent Preterm Birth
    Pregnant women who have a shortened cervix and have previously had a preterm baby are at increased risk for having another preterm baby. This study will determine whether reinforcing the cervix with a surgical stitch can reduce the chance of a preterm birth.
  • Biological Mechanisms Underlying Preterm Birth
    This study aims to investigate the basic mechanisms of preterm labor by systematically cataloging the changes in expression levels of all expressed genes whose sequences are available. The goals will be accomplished by using microarray technology followed by subsequent confirmative or complementary analyses.
  • Glyburide and Metformin for GDM
    A pharmacokinetic and pharmacodynamic study evaluating glyburide, metformin, and combination treatment for gestational diabetes mellitus.

NICHD Clinical Trials

ClinicalTrials.gov Search Results

Information on current NIH-sponsored clinical trials on high-risk pregnancy is available by following the link below or by calling 800-411-1222.

top of pageBACK TO TOP